Evidence map›Paper›PMID 43022087›Full record

ArticleKidney international reports2026

Cardiovascular Outcomes of Triglyceride-Targeting Lipid-Lowering Therapies in Patients with CKD.

Mohammad Abdullah Al Zubair Naim, Fridtjof Thomas, Elani Streja, Robert Lowell Davis, Kamyar Kalantar-Zadeh, Keiichi Sumida, Csaba P Kovesdy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mohammad Abdullah Al Zubair NaimDivision of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Fridtjof ThomasDivision of Biostatistics, Department of Preventive Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Elani StrejaDivision of Nephrology, Hypertension, and Kidney Transplantation, Department of Medicine, University of California Irvine School of Medicine, Orange, California, USA.
Robert Lowell DavisDepartment of Pediatrics, Center for biomedical informatics, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Kamyar Kalantar-ZadehDepartment of Medicine, Greater Los Angeles Veterans Affairs Medical Center, Los Angeles, California, USA.
Keiichi SumidaDivision of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Csaba P KovesdyDivision of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA.

Funding

HSRD VA I01 HX002680
6 · The paper itself

Abstract

Introduction: In patients with chronic kidney disease (CKD), atherogenic lipid profiles, characterized by hypertriglyceridemia and impaired high-density lipoprotein cholesterol (HDL-C) metabolism, contribute to adverse cardiovascular disease (CVD) outcomes. Since evidence on CVD outcomes of triglyceride-targeting lipid-lowering therapies (LLTs), such as fibrates and niacin, remains limited, kidney disease guidelines recommend further investigation. Methods: We designed this retrospective cohort study using a target trial emulation framework and leveraged data from a nationwide cohort of 3,562,882 US Veterans to identify 46,904 patients with incident CKD initiating Results: 16,191 patients (event rate, 79.2; 95% confidence interval [CI], 78.0-80.4 per 1000 person-years) experienced MACE after a median follow-up of 3.70 years. The risk of MACE was significantly lower (hazard ratio [HR], 0.93 [95% CI, 0.86-0.99]; Conclusion: In this large nationwide cohort of patients with nonkidney replacement therapy-dependent CKD,

Indexed as

chronic kidney diseasefibrateMACEniacinstatinUS Veterans

Identifiers

PMID43022087
PMCPMC13755577

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.